GARDASIL® Available to Developing Countries through UNICEF Tender

GARDASIL® Available to Developing Countries through UNICEF Tender 
KIRKLAND, QC, May 9, 2013 /CNW Telbec/ - Merck announced today that the 
company has been awarded a significant portion of the UNICEF human 
papillomavirus (HPV) vaccine tender, and will provide sustained supply of 
GARDASIL(®) [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) 
Recombinant Vaccine] to GAVI-eligible countries. This agreement follows the 
GAVI Alliance's earlier announcement that HPV vaccines would be included in 
its portfolio for the first time. GAVI is expected to support the introduction 
of HPV vaccination in 28 countries by the end of 2017. GAVI Alliance is a 
public-private partnership focused on saving children's lives and protecting 
people's health by increasing access to immunization in poor countries. 
Through this initial tender award, Merck expects to supply approximately 2.4 
million doses of GARDASIL to GAVI-eligible countries between 2013 to 2017 to 
help meet vaccine demand for countries already approved or recommended for 
approval by GAVI for HPV vaccine demonstration projects and national 
introductions. Additional awards by UNICEF are anticipated as vaccine demand 
increases. 
"It is essential that every young girl around the world have access to HPV 
vaccines. Today's decision by UNICEF is an important step forward," said Julie 
L. Gerberding, M.D., president, Merck Vaccines. "This partnership highlights 
Merck's commitment to working closely with GAVI to ensure broad and sustained 
access to GARDASIL in the world's poorest countries, where the burden of 
cervical cancer is greatest." 
"A vast gap currently exists between girls in rich and poor countries. With 
today's announcement, GAVI's programmes can begin to bridge that gap so that 
girls can be protected against cervical cancer no matter where they are born," 
said Dr. Seth Berkley, CEO of the GAVI Alliance. "By 2020 we hope to reach 
more than 30 million girls in more than 40 countries. This is a 
transformational moment for the health of women and girls across the world. We 
thank the manufacturers for working with us to help make this happen." 
Following a 2009 report, the World Health Organization recommended that 
routine HPV vaccination be included in national immunization programs to help 
prevent cervical cancer and other HPV-related diseases. It is estimated that 
approximately 500,000 women develop cervical cancer annually around the world, 
with about 85 percent of cases occurring in developing countries. Cervical 
cancer is the third most common type of cancer among women worldwide. 
High-risk HPV types 16 and 18 cause about 75 percent of cervical cancers, 70 
percent of vaginal cancers, 40 to 50 percent of vulvar cancers and 80 percent 
of anal cancers. 
Other Merck access efforts for GARDASIL in the developing world
Merck is pursuing a systematic and thoughtful approach to improve access to 
GARDASIL in the developing world through four key pillars: innovation, 
partnerships, pricing and implementation. Key efforts include: 


    --  In September 2012, Merck announced it will donate 460,000 doses
        of GARDASIL over a two-year period to the Republic of Uganda to
        help the Ministry of Health launch a HPV vaccination program in
        12 districts in the country.  The program represents the first
        phase of Uganda's national rollout plan for HPV vaccination.
    --  In April 2011, the Government of Rwanda, Merck and QIAGEN
        launched a comprehensive cervical cancer prevention program in
        Rwanda incorporating both HPV vaccination and HPV testing, the
        first program of its kind in Africa.  In its initial year, an
        estimated 93 percent of eligible girls 12 to 15 years of age in
        Rwanda were vaccinated with three doses of GARDASIL.
    --  In 2010 Merck partnered with the Royal Government of Bhutan and
        the Australian Cervical Cancer Foundation to launch a six-year
        national vaccination program with GARDASIL for appropriate
        girls and young women between the ages of 12 and 18 in Bhutan. 
        Merck provided GARDASIL to the program partners at no cost in
        the first year and for the remaining five years is providing it
        at an access price.
    --  In 2009 Merck also announced a partnership with QIAGEN N.V.
        focused on increasing access to HPV vaccination and HPV DNA
        testing in some of the most resource-poor areas of the world. 
        This initiative was the first time a vaccine manufacturer and a
        molecular diagnostics company collaborated to help address the
        burden of cervical cancer with a comprehensive approach.
    --  Merck has also donated more than one million doses of GARDASIL
        [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18)
        Recombinant Vaccine] through the GARDASIL Access Program, which
        was established in 2007 to help enable organizations and
        institutions in eligible lowest income countries to gain
        operational experience designing and implementing HPV
        vaccination projects.

For further information about GARDASIL, please consult the product monograph 
available at www.merck.ca.

About Merck
Today's Merck is a global healthcare leader working to help the world be 
well. Merck is known as MSD outside the United States and Canada. Through 
our medicines, vaccines, biologic therapies, and consumer and animal products, 
we work with customers and operate in more than 140 countries to deliver 
innovative health solutions. We also demonstrate our commitment to increasing 
access to healthcare through far-reaching policies, programs and partnerships. 
For more information about our operations in Canada, visit www.merck.ca.

Merck Forward-Looking Statement
This news release includes "forward-looking statements" within the meaning of 
the safe harbor provisions of the United States Private Securities Litigation 
Reform Act of 1995. These statements are based upon the current beliefs and 
expectations of Merck's management and are subject to significant risks and 
uncertainties. If underlying assumptions prove inaccurate or risks or 
uncertainties materialize, actual results may differ materially from those set 
forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry 
conditions and competition; general economic factors, including interest rate 
and currency exchange rate fluctuations; the impact of pharmaceutical industry 
regulation and health care legislation in the United States and 
internationally; global trends toward health care cost containment; 
technological advances, new products and patents attained by competitors; 
challenges inherent in new product development, including obtaining regulatory 
approval; Merck's ability to accurately predict future market conditions; 
manufacturing difficulties or delays; financial instability of international 
economies and sovereign risk; dependence on the effectiveness of Merck's 
patents and other protections for innovative products; and the exposure to 
litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking 
statement, whether as a result of new information, future events or otherwise. 
Additional factors that could cause results to differ materially from those 
described in the forward-looking statements can be found in Merck's 2012 
Annual Report on Form 10-K and the company's other filings with the Securities 
and Exchange Commission (SEC) available at the SEC's Internet site 
(www.sec.gov).

GARDASIL(®) is a registered trademark of Merck & Co., Inc., Whitehouse 
Station, N.J., U.S.A.

Ani Armenian Merck 514.428.3395

SOURCE: MERCK CANADA INC.

To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/May2013/09/c4966.html

CO: MERCK CANADA INC.
ST: Quebec
NI: MTC HEA * ORDER 

-0- May/09/2013 11:20 GMT